Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44)

The summary for the Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44): This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of innovative technologies that may advance progress toward more effective cell replacement therapies for type 1 diabetes (T1D).
Federal Grant Title: Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44)
Federal Agency Name: National Institutes of Health
Grant Categories: Food and Nutrition Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DK-16-004
Type of Funding: Grant
CFDA Numbers: 93.847
CFDA Descriptions: Diabetes, Digestive, and Kidney Diseases Extramural Research
Current Application Deadline: Jun 28, 2016
Original Application Deadline: Jun 28, 2016
Posted Date: Nov 19, 2015
Creation Date: Nov 19, 2015
Archive Date: Jul 29, 2016
Total Program Funding: $3,000,000
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-004.html
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors...
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Requ...
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...
Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
Molecular Therapy Core Centers
Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com